Power Law company profile

Editas Medicine

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2016 Unicorn

Unlocking the promise of genome editing to deliver life-changing medicines

Valuation

$164M

Market cap · May/2026

Revenue

$41M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $1B+ revenueColt · Power Law growth-stage

Investors

17 investors on Editas Medicine's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage

Partners Innovation Fund

Series B+ 12 investors entered at this stage

Khosla Ventures

Viking Global Investors

Alexandria Venture Investments

Omega Funds

T. Rowe Price

Harvard University

Casdin Capital

Fidelity Investments

EcoR1 Capital

Boris Nikolic

Deerfield

Jennison Associates

Editas Medicine mafia

Startups founded by Editas Medicine alumni

Former Editas Medicine employees who went on to start their own companies. Sorted by Dealroom signal score.

FitbiomicsEst. 2018

George ChurchUnited States

Signal score87

Beam TherapeuticsEst. 2017

JJJ. Keith JoungUnited States

Signal score78

Rubius TherapeuticsEst. 2013

JMJordi Mata-FinkUnited States

Signal score73

PairwiseEst. 2017

Keith JoungUnited States

Signal score73

Arbor BiotechnologiesEst. 2016

FZFeng ZhangUnited States

Signal score65

Mammoth BiosciencesEst. 2017

Jennifer A. DoudnaUnited States

Signal score64

Stratus TherapeuticsEst. 2021

David ScaddenUnited States

Signal score62

Book a demo to explore the full alumni network →

Global footprint

Where Editas Medicine has talent and traffic

AI talent share

1.1% of workforce is AI talent
(2 of 183 staff)

Core AI10.55%

Other AI10.55%

Non-AI workforce18198.91%

Workforce by country

2 countries with
team presence

🇺🇸 United States99.4%

🇮🇳 India0.6%

2 countries shown

Web traffic by country

18K monthly visits
across markets

🇺🇸 United States80%

🇩🇪 Germany7.2%

🇨🇦 Canada6.1%

🇮🇳 India4.4%

🇦🇺 Australia1.1%

Top 5 markets shown

Patent intelligence

$69M patent portfolio · 74 active families

Estimated portfolio value

$69M

41.9% of market cap · 29.5× smaller than top peer Ablynx ($2B)

74 active patent families

Where Editas Medicine innovates Molecular biologyBioinformaticsCellCRISPRCell biology

Where Editas Medicine concentrates vs peers

Each axis is a top-10 topic across Editas Medicine and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Editas Medicine

An AI-synthesized read of the highest-engagement posts about Editas Medicine on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Editas Medicine on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles